Cohance Lifesciences Limited vs Ajanta Pharma Limited
Last updated: 6 November 2026
MoneyDock presents a comparative analysis between Cohance Lifesciences Limited (COHANCE.NS) and Ajanta Pharma Limited (AJANTPHARM.NS), two prominent players in the Indian pharmaceutical sector. While both operate within the broader healthcare industry, they may focus on different therapeutic areas or market segments, making a direct comparison of their financial metrics crucial for investors seeking to understand their relative strengths and weaknesses. This article leverages key financial data to offer insights into their current market standing, historical performance, and potential outlook for various investor profiles.
Key Financial Metrics Comparison
| Metric | Cohance Lifesciences Limited | Ajanta Pharma Limited |
|---|---|---|
| Current Price | ₹449.00 | ₹3282.10 |
| 52-Week High | ₹537.35 | ₹3672.80 |
| 52-Week Low | ₹279.90 | ₹2680.90 |
| 1-Year Return | -16.44% | 22.39% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When evaluating Cohance Lifesciences and Ajanta Pharma, several aspects stand out from the provided data. In terms of valuation, the absence of Trailing P/E and Market Cap for both companies makes a direct valuation comparison challenging based solely on these metrics. However, we can look at their current prices relative to their 52-week ranges. Cohance Lifesciences is currently trading at ₹449.00, which is closer to its 52-week high of ₹537.35 than its 52-week low of ₹279.90. This suggests it has recovered from its lows but is still below its peak. Ajanta Pharma, on the other hand, trades at ₹3282.10, also positioned closer to its 52-week high of ₹3672.80, with a 52-week low of ₹2680.90.
Regarding returns, Ajanta Pharma Limited clearly outperforms Cohance Lifesciences Limited over the past year. Ajanta Pharma delivered a robust 1-Year Return of 22.39%, indicating strong positive momentum and investor confidence. In contrast, Cohance Lifesciences registered a negative 1-Year Return of -16.44%, suggesting a period of underperformance or correction. This significant difference in returns highlights Ajanta Pharma's stronger recent stock performance.
For stability, considering the 52-week ranges, both stocks have experienced fluctuations. Cohance's range from ₹279.90 to ₹537.35 represents a significant swing. Ajanta Pharma's range from ₹2680.90 to ₹3672.80 also shows volatility, but its positive 1-year return suggests that despite these fluctuations, it has trended upwards overall. Without more in-depth financial statements or market cap figures, it's difficult to definitively declare one more 'stable' than the other based purely on price ranges, but Ajanta Pharma's positive return indicates better recent price stability in terms of overall growth.
MoneyDock Verdict
For Aggressive Investors: Ajanta Pharma Limited appears more attractive. Its strong 1-year return of 22.39% indicates growth potential and momentum, which typically aligns with an aggressive investment strategy. While Cohance Lifesciences might be seen as a value play after its decline, the negative returns present higher immediate risk.
For Conservative Investors: Given the data, neither stock offers explicit indicators for conservative investors without P/E and Market Cap data to assess fundamental stability. However, Ajanta Pharma's positive and substantial 1-year return suggests a more favorable recent track record compared to Cohance Lifesciences' negative return, making it potentially less volatile in terms of capital depreciation over the short term.
For Long-Term SIP Investors: Ajanta Pharma Limited seems to be a more promising candidate for long-term SIP (Systematic Investment Plan) investors. Its consistent positive 1-year return suggests an underlying growth trajectory that could benefit from rupee-cost averaging. Cohance Lifesciences, with its negative return, might require a deeper dive into its turnaround strategy before committing to a long-term SIP.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.